Add-On Reslizumab Lowers Asthma Exacerbation Rates in Aspirin-Sensitive Patients
Reslizumab appears to improve clinical asthma exacerbation rates among patients with Aspirin Exacerbated Respiratory Disease (AERD)
Reslizumab appears to improve clinical asthma exacerbation rates among patients with Aspirin Exacerbated Respiratory Disease (AERD)
Study data from a randomized, double-blind, placebo-controlled trial of prasugrel for the treatment of AERD presented at the 2017 AAAAI Annual Meeting.